|
Dr. Carter the co-inventor of Ampligen® joined the Company in 1978 and has served as the Company's Chief Scientific Officer since May 1989 the Chairman of the Company's Board of Directors since January 1992 the Company's Chief Executive Officer since July 1993 the Company's President since April 1995 and a director since 1987. From 1987 to 1988 Dr. Carter served as the Company's Chairman. Dr. Carter was a leading innovator in the development of human interferon for a variety of treatment indications including various viral diseases and cancer. In this context he received the first FDA approval to initiate clinical trials on a beta interferon product manufactured in the U.S. under his supervision. From 1985 to October 1988 Dr. Carter served as the Company's Chief Executive Officer and Chief Scientist. He received his M.D. degree from Duke University and underwent his post-doctoral training at the National Institutes of Health and Johns Hopkins University. Dr. Carter also served as Professor of Neoplastic Diseases at Hahneman Medical University a position he held from 1980 to 1998. He also served as Director of Clinical Research for Hahneman Medical University's Institute for Cancer and Blood Diseases and as a professor at Johns Hopkins School of Medicine and the State University of New York at Buffalo. He is a Board certified physician and author of more than 200 scientific articles including the editing of various textbooks on anti-viral and immune therapy. | 